Investor Presentaiton

Business Performance 2Q/FY24 Tracking in-line; Rebound led by Non-ARV API + FDF business 2Q/FY24 Segment Performance [Crore] 1Q/FY24 2Q/FY24 2Q/FY23 Y-o-Y Q-o-Q FDF 285 332 149 APIs 597 629 680 123% -8% 16% 5% CDMO-Synthesis 250 224 720 -69% Bio 50 39 27 44% -10% -22% Total Revenues 1,182 1,224 1,576 -22% 4% 19 CDMO-Synthesis 18% Bio 3% APIs 52% 2Q/FY24 Business Mix FDF 27% Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 ■ Formulation (FDF): Sharp rebound; +16% QoQ following ARV offtake by global agencies and stable pricing. Strong YoY driven by low base last year. Overall underlying demand trend remains healthy. Developed market growth supported by market share expansion ■ APIs: Improved +5% sequentially though declined YoY. Onco bounced back on skewed increased demand (+117%). ARV continued its volume led steady momentum although declined 8% both YoY and QoQ CDMO-Synthesis: Revenues declined due to YoY comparison given large PO executed last year. Otherwise, Baseline business tracking healthy and project pipeline continues to scale up. Commercial scale validations supplies for animal health product started ■ Bio: Strong growth +44% YoY, led by traction in CDMO business. Downstream expansion at R2 on-line from Dec'23 while new R3 site design finalized to strengthen expertise in r-protein and Growth factors. Acquired additional 13.2% stake of Laurus Bio for ~72 Cr LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation